Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWJ1421 vs DWC201903 in Healthy Male Volunteers
NCT04278391Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib oral solution in rheumatoid arthritis (RA) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 14 hours and Area Under the Curve to the last measurable concentration at 14 hours. Started Jul 2019; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04278391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278391.